← Back to patent-cliff list
布地奈德/富马酸福莫特/格隆溴铵
Tier B — Position earlyBudesonide/Formoterol fumarate/Glycopyrronium Bromide
阿斯利康
Originator
2019
First approval
-
Expiry (public)
$1.2B ▲
Peak sales
化学药
Type
Targets：mAChRs、ADRB2、GR
Brand：Breztri Aerosphere、Breztri、Trixeo Aerosphere
Indications (approved)：哮喘、慢性阻塞性肺疾病
Regional status
US
批准上市
2020-07-23
EU
批准上市
2020-12-09
China
批准上市
2019-12-18
Japan
批准上市
2019-06-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Budesonide/Formoterol fumarate/Glycopyrronium Bromide?
Approved indications include: 哮喘, 慢性阻塞性肺疾病.
When does the Budesonide/Formoterol fumarate/Glycopyrronium Bromide patent expire?
No public expiry year is available for Budesonide/Formoterol fumarate/Glycopyrronium Bromide yet; this page updates once verified.
How do I get a quote for Budesonide/Formoterol fumarate/Glycopyrronium Bromide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24